Acutaas Chemicals Limited — PPTs, 16-05-2026: Investor Presentation

Acutaas Chemicals delivered strong financial performance in FY26.

**Business Performance:** Revenue from Operations surged to ₹1,339.4 Cr, a 33% year-on-year increase. Profit After Tax more than doubled to ₹356.4 Cr, marking a 122% jump. Pharmaceutical Intermediates remains the dominant segment, contributing 88% of revenue. The company also reported a robust EBITDA margin of 35.9% and healthy ROCE/ROE at 39.3% and 32.5% respectively.

**Growth Drivers or Strategy:** The company is strategically expanding, focusing on CDMO opportunities in pharmaceuticals and pioneering new-edge segments like semiconductor and battery chemicals. Significant capex of over ₹1,000 Cr is planned until FY30, including capacity expansion in pharma and establishing advanced facilities for semiconductor chemicals via a South Korea JV.

**Recent Developments:** Notable updates include the rebranding to Acutaas Chemicals Ltd. and the formation of Indichem Inc., a joint venture in South Korea for advanced semiconductor chemicals. The company also inaugurated Phase 1 of its Battery Chemicals manufacturing facility.

**Key Financial Metrics:** FY26 Revenue: ₹1,339.4 Cr (+33% YoY). PAT: ₹356.4 Cr (+122% YoY). EBITDA Margin: 35.9%.

**Management Commentary / Outlook:** Management is investing aggressively in sustainable future growth, earmarking over ₹1,000 Cr for capex until FY30 across pharma, semiconductor, and battery chemical segments, alongside R&D and solar power initiatives.